Skip to main content
SpringerLink
Log in

Follicular Neutrophilic Inflammation (Hidradenitis Suppurativa)

  • Chapter
  • First Online:
Neutrophilic Dermatoses

  • 661 Accesses

Abstract

Follicular neutrophilic inflammation or Hidradenitis Suppurativa (HS), also known as acne inversa, is a chronic-relapsing, debilitating inflammatory disease of the hair follicle that usually presents after puberty, affecting apocrine gland-bearing skin, most commonly the axillae, inguinal regions and anogenital area [1]. It is clinically characterized by recurrent, painful, deep-seated nodules commonly ending in abscesses and sinus tracts with suppuration and hypertrophic scarring [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–64.

    Article  CAS  PubMed  Google Scholar 

  2. Miller IM, McAndrew RJ, Hamzavi I. Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin. 2016;34:7–16.

    Article  CAS  PubMed  Google Scholar 

  3. Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–44.

    Article  CAS  PubMed  Google Scholar 

  4. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422–34.

    Article  CAS  PubMed  Google Scholar 

  5. Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65:790–8.

    Article  CAS  PubMed  Google Scholar 

  6. Marzano AV, Ceccherini I, Gattorno M, et al. Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. Medicine (Baltimore). 2014;93:e187.

    Article  CAS  Google Scholar 

  7. Feldmeyer L, Werner S, French LE, Beer HD. Interleukin-1, inflammasomes and the skin. Eur J Cell Biol. 2010;89:638–44.

    Article  CAS  PubMed  Google Scholar 

  8. Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73(5 Suppl 1):S4–7.

    Article  PubMed  Google Scholar 

  9. Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Derm. 2013;133:97–103.

    Article  CAS  PubMed  Google Scholar 

  10. Sung S, Kimball AB. Counterpoint: analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;69:818–9.

    Article  PubMed  Google Scholar 

  11. Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68:412–9.

    Article  PubMed  Google Scholar 

  12. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596–601.

    Article  PubMed  Google Scholar 

  13. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191–4.

    Article  CAS  PubMed  Google Scholar 

  14. Jemec GB. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol. 1988;119:345–50.

    Article  CAS  PubMed  Google Scholar 

  15. van der Zee HH, Jemec GB. New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes. J Am Acad Dermatol. 2015;73:S23–6.

    Article  PubMed  Google Scholar 

  16. Revuz J. Hidradenitis suppurativa. Presse Med. 2010;39:1254–64.

    Article  PubMed  Google Scholar 

  17. Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. 2013;133:1506–11.

    Article  CAS  PubMed  Google Scholar 

  18. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409–15.

    Article  PubMed  Google Scholar 

  19. Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013;149:762–4.

    Article  PubMed  Google Scholar 

  20. Marzano AV, Borghi A, Stadnicki A, et al. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20:213–27.

    Article  PubMed  Google Scholar 

  21. Marzano AV, Ramoni S, Caputo R. Amicrobial pustulosis of the folds. Report of 6 cases and a literature review. Dermatology. 2008;216:305–11.

    Article  PubMed  Google Scholar 

  22. Marzano AV, Tavecchio S, Berti E, et al. Cytokine and chemokine profile in amicrobial pustulosis of the folds: evidence for autoinflammation. Medicine (Baltimore). 2015;94:e2301.

    Article  CAS  Google Scholar 

  23. Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigh RRH, editor. Dermatologic surgery. New York: Marcel Dekker; 1989. p. 729–39.

    Google Scholar 

  24. Sartorius K, Lapins J, Emtestam L, Jemec GB. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol. 2003;149:211–3.

    Article  CAS  PubMed  Google Scholar 

  25. Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161:831–9.

    Article  CAS  PubMed  Google Scholar 

  26. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;18:846–55.

    Article  Google Scholar 

  27. Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205–17.

    Article  CAS  PubMed  Google Scholar 

  28. Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171:1434–42.

    Article  CAS  PubMed  Google Scholar 

  29. Chiricozzi A, Faleri S, Franceschini C, et al. AISI: a new disease severity assessment tool for hidradenitis suppurativa. Wounds. 2010;27:258–64.

    Google Scholar 

  30. Smith HS, Chao JD, Teitelbaum J. Painful hidradenitis suppurativa. Clin J Pain. 2010;26:435–44.

    Article  PubMed  Google Scholar 

  31. Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol. 2010;62:706–8.

    Article  PubMed  Google Scholar 

  32. Wolkenstein P, Loundou A, Barrau K, et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol. 2007;56:621–3.

    Article  PubMed  Google Scholar 

  33. Kurek A, Peters EM, Chanwangpong A, et al. Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol. 2012;67:e1.

    Article  Google Scholar 

  34. Gooderham M, Papp K. The psychosocial impact of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73:S19–22.

    Article  PubMed  Google Scholar 

  35. Wortsman X, Moreno C, Soto R, et al. Ultrasound in-depth characterization and staging of hidradenitis suppurativa. Dermatol Surg. 2013;39:1835–42.

    Article  CAS  PubMed  Google Scholar 

  36. Wortsman X, Castro A, Figueroa A. Color Doppler ultrasound assessment of morphology and types of fistulous tracts in hidradenitis suppurativa (HS). J Am Acad Dermatol. 2016;75:760–7.

    Article  PubMed  Google Scholar 

  37. Zarchi K, Yazdanyar N, Yazdanyar S, et al. Pain and inflammation in hidradenitis suppurativa correspond to morphological changes identified by high-frequency ultrasound. J Eur Acad Dermatol Venereol. 2015;29:527–32.

    Article  CAS  PubMed  Google Scholar 

  38. Damiani G, Della Valle V, Iannone M, et al. Autoinflammatory Disease Damage Index (ADDI): a possible newborn also in hidradenitis suppurativa daily practice. Ann Rheum Dis. 2017;76(8):e25. pii: annrheumdis-2016-210901.

    Article  PubMed  Google Scholar 

  39. Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73:S27–35.

    Article  PubMed  Google Scholar 

  40. Sabat R, Chanwangpong A, Schneider-Burrus S, et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012;7:e31810.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol. 2014;71:1144–50.

    Article  PubMed  Google Scholar 

  42. Kromann CB, Deckers IE, Esmann S, et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171:819–24.

    Article  CAS  PubMed  Google Scholar 

  43. Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinology. 2010;2:9–16.

    Article  Google Scholar 

  44. Egeberg A, Jemec GB, Kimball AB, et al. Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa. J Invest Dermatol. 2017;137(5):1060–4. pii: S0022-202X(17)30011-3018.

    Article  CAS  PubMed  Google Scholar 

  45. Richette P, Molto A, Viguier M, et al. Hidradenitis suppurativa associated with spondyloarthritis—results from a multicenter national prospective study. J Rheumatol. 2014;41:490–4.

    Article  PubMed  Google Scholar 

  46. Marzano AV, Ishak RS, Colombo A, et al. Pyoderma gangrenosum, acne and suppurative hidradenitis syndrome following bowel bypass surgery. Dermatology. 2012;225:215–9.

    Article  PubMed  Google Scholar 

  47. Lapins J, Ye W, Nyrén O, Emtestam L. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol. 2001;137:730–4.

    CAS  PubMed  Google Scholar 

  48. Meixner D, Schneider S, Krause M, et al. Acne inversa. J Dtsch Dermatol Ges. 2008;6:189–96.

    Article  PubMed  Google Scholar 

  49. Verneuil A. Études sur les tumeurs de la peau; des quelques maladies des glandes sudoripares. Arch Gen Med. 1854;IV:447–68.

    Google Scholar 

  50. Verneuil A. De l’hidrosadénite phlegmoneuse et des abcés sudoripares. Arch Gén Méd. 1864;2:537–57.

    Google Scholar 

  51. Shelley WB, Cahn MM. The pathogenesis of hidradenitis suppurativa in man. Arch Dermatol. 1955;72:562.

    Article  CAS  Google Scholar 

  52. Brunsting HA. Hidradenitis suppurativa; abscess of the apocrine sweat glands. Arch Derm Syphilol. 1939;39:108–20.

    Article  Google Scholar 

  53. Brunsting HA. Hidradenitis and other variants of acne. Arch Derm Syphilol. 1952;65:303–15.

    Article  CAS  Google Scholar 

  54. Pillsbury DM, Shelley WB, Kligman AM. Bacterial infections of the skin. In: Pillsbury DM, Shelley WB, Kligman AM, editors. Dermatology. 1st ed. Philadelphia: Saunders; 1956. p. 459–98.

    Google Scholar 

  55. Plewig G, Kligman AM. Acne morphogenesis and treatment. Berlin: Springer; 1975. p. 192.

    Google Scholar 

  56. Yu CC-W, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol. 1990;122:763–9.

    Article  CAS  PubMed  Google Scholar 

  57. Plewig G, Steger M. Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Marks R, Plewig G, editors. Acne and related disorders. London: Martin Dunitz; 1989. p. 345–57.

    Google Scholar 

  58. Jemec GB, Hansen U. Histology of hidradenitis suppurativa. J Am Acad Dermatol. 1996;34:994–9.

    Article  CAS  PubMed  Google Scholar 

  59. Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73:S8–S11.

    Article  CAS  PubMed  Google Scholar 

  60. Wang B, Yang W, Wen W, et al. Gamma-secretase gene mutations in familial acne inversa. Science. 2010;330:1065.

    Article  CAS  PubMed  Google Scholar 

  61. Pink AE, Simpson MA, Desai N, et al. Mutations in the gamma-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol. 2012;132:2459–61.

    Article  CAS  PubMed  Google Scholar 

  62. Pink AE, Simpson MA, Brice GW, et al. PSENEN and NCSTN mutations in familial hidradenitis suppurativa (Acne Inversa). J Invest Dermatol. 2011;131:1568–70.

    Article  CAS  PubMed  Google Scholar 

  63. Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity. 2010;32:14–27.

    Article  CAS  PubMed  Google Scholar 

  64. Melnik BC, Plewig G. Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: an approach to pathogenesis by evidence from translational biology. Exp Dermatol. 2013;22:172–7.

    Article  CAS  PubMed  Google Scholar 

  65. Gentle ME, Rose A, Bugeon L, et al. Noncanonical notch signaling modulates cytokine responses of dendritic cells to inflammatory stimuli. J Immunol. 2012;189:1274–84.

    Article  CAS  PubMed  Google Scholar 

  66. Miller I, Lynggaard CD, Lophaven S, et al. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165:391–8.

    Article  CAS  PubMed  Google Scholar 

  67. Lima AL, Karl I, Giner T, et al. Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br J Dermatol. 2016;174:514–21.

    Article  CAS  PubMed  Google Scholar 

  68. Cho KA, Suh JW, Lee KH, et al. IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1b by keratinocytes via the ROS-NLRP3-caspase-1 pathway. Int Immunol. 2012;24:147–58.

    Article  CAS  PubMed  Google Scholar 

  69. Dréno B, Khammari A, Brocard A, et al. Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol. 2012;148:182–6.

    Article  PubMed  CAS  Google Scholar 

  70. Hofmann SC, Saborowski V, Lange S, et al. Expression of innate defense antimicrobial peptides in hidradenitis suppurativa. J Am Acad Dermatol. 2012;66:966–74.

    Article  CAS  PubMed  Google Scholar 

  71. Hunger RE, Surovy AM, Hassan AS, et al. Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C-type lectin receptor. Br J Dermatol. 2008;158:691–7.

    Article  CAS  PubMed  Google Scholar 

  72. Schlapbach C, Yawalkar N, Hunger RE. Human beta-defensin-2 and psoriasin are overexpressed in lesions of acne inversa. J Am Acad Dermatol. 2009;61:58–65.

    Article  CAS  PubMed  Google Scholar 

  73. van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164:1292–8.

    Article  PubMed  CAS  Google Scholar 

  74. Kurayev A, Ashkar H, Saraiya A, Gottlieb AB. Hidradenitis suppurativa: review of the pathogenesis and treatment. J Drugs Dermatol. 2016;15:1017–22.

    CAS  PubMed  Google Scholar 

  75. van der Zee HH, Laman JD, de Ruiter L, et al. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. Br J Dermatol. 2012;166:298–305.

    Article  PubMed  CAS  Google Scholar 

  76. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60:539–61.

    Article  PubMed  Google Scholar 

  77. Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016;175:882–91.

    Article  CAS  PubMed  Google Scholar 

  78. Marzano AV, Menicanti C, Crosti C, Trevisan V. Neutrophilic dermatoses and inflammatory bowel diseases. G Ital Dermatol Venereol. 2013;148:185–96.

    CAS  PubMed  Google Scholar 

  79. Marzano A, Damiani G, Ceccherini I, et al. Autoinflammation in pyoderma gangrenosum and its syndromic form PASH. Br J Dermatol. 2016;176(6):1588–98. https://doi.org/10.1111/bjd.15226.

    Article  CAS  Google Scholar 

  80. Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol. 2009;89:601–3.

    Article  CAS  PubMed  Google Scholar 

  81. Satoh TK, Mellett M, Contassot E, French LE. Are neutrophilic dermatoses autoinflammatory disorders? Br J Dermatol. 2016. https://doi.org/10.1111/bjd.15105. [Epub ahead of print].

  82. Nikolakis G, Join-Lambert O, Karagiannidis I, et al. Bacteriology of hidradenitis suppurativa/acne inversa: a review. J Am Acad Dermatol. 2015;73(5 Suppl 1):S12–8.

    Article  PubMed  Google Scholar 

  83. Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol. 2016;174:970–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546–9.

    Article  CAS  PubMed  Google Scholar 

  85. Alavi A, Kirsner RS. Local wound care and topical management of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73:S55–61.

    Article  PubMed  Google Scholar 

  86. Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22:325–8.

    Article  CAS  PubMed  Google Scholar 

  87. Alhusayen R, Shear NH. Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015;73:S42–6.

    Article  PubMed  Google Scholar 

  88. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258–65.

    Article  PubMed  Google Scholar 

  89. Mendonça CO, Griffiths CE. Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol. 2006;154:977–8.

    Article  PubMed  CAS  Google Scholar 

  90. Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219:148–54.

    Article  CAS  PubMed  Google Scholar 

  91. van der Zee HH, Boer J, Prens EP, Jemec GB. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219:143–7.

    Article  PubMed  CAS  Google Scholar 

  92. Bettoli V, Zauli S, Borghi A, et al. Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol. 2014;28:125–6.

    Article  CAS  PubMed  Google Scholar 

  93. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971–4.

    Article  CAS  PubMed  Google Scholar 

  94. Kaur MR, Lewis HM. Hidradenitis suppurativa treated with dapsone: a case series of five patients. J Dermatolog Treat. 2006;17:211–3.

    Article  CAS  PubMed  Google Scholar 

  95. Yazdanyar S, Boer J, Ingvarsson G, et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222:342–6.

    Article  CAS  PubMed  Google Scholar 

  96. Hogan DJ, Light MJ. Successful treatment of hidradenitis suppurativa with acitretin. J Am Acad Dermatol. 1988;19:355–6.

    Article  CAS  PubMed  Google Scholar 

  97. Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011;164:170–5.

    Article  CAS  PubMed  Google Scholar 

  98. Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol. 2014;171:170–4.

    Article  CAS  PubMed  Google Scholar 

  99. Verdolini R, Simonacci F, Menon S, Pavlou P, Mannello B. Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age. G Ital Dermatol Venereol. 2015;150:155–62.

    CAS  PubMed  Google Scholar 

  100. Brocard A, Dreno B. Innate immunity: a crucial target for zinc in the treatment of inflammatory dermatosis. J Eur Acad Dermatol Venereol. 2011;25:1146–52.

    Article  CAS  PubMed  Google Scholar 

  101. Sawers RS, Randall VA, Ebling FJ. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy. Br J Dermatol. 1986;115:269–74.

    Article  CAS  PubMed  Google Scholar 

  102. Stellon AJ, Wakeling M. Hidradenitis suppurativa associated with use of oral contraceptives. BMJ. 1989;298:28–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Mortimer PS, Dawber RP, Gales MA, et al. A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115:263–8.

    Article  CAS  PubMed  Google Scholar 

  104. Blok JL, van Hattem S, Jonkman MF, Horváth B. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168:243–52.

    Article  CAS  PubMed  Google Scholar 

  105. Lee RA, Eisen DB. Treatment of hidradenitis suppurativa with biologic medications. J Am Acad Dermatol. 2015;73:S82–8.

    Article  CAS  PubMed  Google Scholar 

  106. Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230:27–33.

    Article  CAS  PubMed  Google Scholar 

  107. Gisondi P, Girolomoni G. Impact of TNF-α antagonists on the quality of life in selected skin diseases. G Ital Dermatol Venereol. 2013;148:243–8.

    CAS  PubMed  Google Scholar 

  108. Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146:501–4.

    CAS  PubMed  Google Scholar 

  109. Gulliver WP, Jemec GB, Baker KA. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2012;26:911–4.

    Article  CAS  PubMed  Google Scholar 

  110. Sharon VR, Garcia MS, Bagheri S, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol. 2012;92:320–1.

    Article  CAS  PubMed  Google Scholar 

  111. Zarchi K, Dufour DN, Jemec GB. Successful treatment of severe hidradenitis suppurativa with anakinra. JAMA Dermatol. 2013;149:1192–4.

    Article  PubMed  Google Scholar 

  112. Deckers IE, van der Zee HH, Balak DM, Prens EP. Fumarates, a new treatment option for therapy-resistant hidradenitis suppurativa: a prospective open-label pilot study. Br J Dermatol. 2015;172:828–9.

    Article  CAS  PubMed  Google Scholar 

  113. Danby FW, Hazen PG, Boer J. New and traditional surgical approaches to hidradenitis suppurativa. J Am Acad Dermatol. 2015;73:S62–5.

    Article  PubMed  Google Scholar 

  114. van Hattem S, Spoo JR, Horváth B, et al. Surgical treatment of sinuses by deroofing in hidradenitis suppurativa. Dermatol Surg. 2012;38:494–7.

    Article  PubMed  CAS  Google Scholar 

  115. Kohorst JJ, Baum CL, Otley CC, et al. Surgical management of hidradenitis suppurativa: outcomes of 590 consecutive patients. Dermatol Surg. 2016;42:1030–40.

    Article  CAS  PubMed  Google Scholar 

  116. Gulliver W, Zoubolis CC, Prens E, et al. Evidence-based approach to the treatment of hidradentis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17:343–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Unità Operativa di Dermatologia, IRCCS Fondazione Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Italy

    Angelo Valerio Marzano & Giovanni Damiani

  2. Dipartimento di Scienze Mediche, Sezione di Dermatologia e Malattie Infettive, Università degli Studi di Ferrara, Ferrara, Italy

    Alessandro Borghi

Authors
  1. Angelo Valerio Marzano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni Damiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Borghi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelo Valerio Marzano .

Editor information

Editors and Affiliations

  1. Physician (Hon.) of Paris Hospitals, Paris, France

    Daniel Wallach

  2. Pathology Department, APHP Hôpital Saint Louis, Paris, France

    Marie-Dominique Vignon-Pennamen

  3. Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Universita’ degli Studi di Milano, Unita’ Operativa di Dermatologia, IRCCS Fondazione Ca’ Granda, Ospedale Maggiore Policlinico, Milano, Italy

    Angelo Valerio Marzano

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Marzano, A.V., Damiani, G., Borghi, A. (2018). Follicular Neutrophilic Inflammation (Hidradenitis Suppurativa). In: Wallach, D., Vignon-Pennamen, MD., Valerio Marzano, A. (eds) Neutrophilic Dermatoses. Springer, Cham. https://doi.org/10.1007/978-3-319-72649-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-72649-6_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-72648-9

  • Online ISBN: 978-3-319-72649-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation